Strikingly, tumor regression was drastically enhanced in Cyld-deficient tumor-bearing mice treated with anti-PD-1, and most of the mice achieved a complete (9/26) or partial response (6/26) two weeks post treatment (Figures 5A, B). This evidence concerns the gene SPATA2 and neoplasm.